Lack of follow-up finance in 2011 for European biotech
This article was originally published in Scrip
Executive Summary
In 2011 so far, almost as many European biotechnology companies have received seed or series A venture finance as their counterparts in North America. However, the early sums raised by European firms are 30-40% less than those in North America. Furthermore, and perhaps more importantly, the number of later finance rounds in Europe is only just over a quarter of that in the US and Canada, suggesting that Europe’s emergent industry must continue to learn to live without a fully supportive financial infrastructure.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.